Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical,
corporate and financial update for the year ended December 31, 2018. Among
other highlights, Genprex reached various milestones in 2018 and early 2019
which included completing its initial public offering (“IPO”) and listing of
common stock on NASDAQ Capital Market, completing a $10 million private
placement, and securing a contract with Accenture to provide clinical data
management services to help fast-track the clinical development of
Oncoprex(TM). “Over the past year, we made great progress in advancing the
development of our gene therapy platform, including Oncoprex(TM) immunogene
therapy for non-small cell lung cancer,” Genprex Chairman and CEO Rodney Varner
stated in the news release. “I’m pleased with our progress and am excited to
continue development of our gene therapies for cancer into 2019 and beyond. I’m
confident, given all we’ve accomplished in the past year, that 2019 will be a
landmark year for Genprex.”
To view the full press release, visit http://ibn.fm/yM4ao
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer fighting genes by encapsulating them into nanoscale hollow spheres
called nanovesicles, which are then administered intravenously and taken up by
tumor cells where they express proteins that are missing or found in low
quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells, and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
